Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba21d776c6f4591765c3922e556f72c2 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16134 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-295 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 |
filingDate |
2016-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2018-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4a6c1d8330ff0b339c840f1f8f468b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee6ff180d3a5f0422677181c2aaff084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f31c098b076fe467a66de09397eab70 |
publicationDate |
2018-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-10149901-B2 |
titleOfInvention |
Influenza vaccines with reduced amounts of squalene |
abstract |
Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 μg/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2221315-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11707520-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11246921-B2 |
priorityDate |
2009-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |